NCT00373906已完成2 期
Phase II Trial pf Bortezomib in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 16
- 主要终点
- to evaluate the clinical potential of bortezomib
研究概览
简要总结
Bortezomib for treatment of disseminated MALT lymphoma or at relapse following HP -eradication,or chemotherapy or radiation.
详细描述
The objectives of this study are to evaluate the effectivity and the safety of bortezomib in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation.
It is a phase II prospective single arm study with a target sample of 16 patients. 1.5mg/m2 Bortezomib is given intravenously on day 1,4,8,11 every three week, for a maximum of 8cycles.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients with histologically confirmed MALT lymphoma with measurable disease (stage I-IV)
- •with first or greater relapse after HP-eradication, radiation or chemotherapy ,
- •age > 18 years
- •must be able to tolerate therapy and have adequate cardiac, renal and hepatic function
- •ECOG status of <_ 2
- •must be capable of understanding the purpose of the study and given written informed consent
排除标准
- 未提供
结局指标
主要结局
to evaluate the clinical potential of bortezomib
to induce objective/histologic responses in patients with MALT-Lymphoma
次要结局
- to evaluate the impact of bortezomib on progression free survival
研究者
相似试验
已完成
2 期
A phase II study of Bortezomib for relapsed/refractory adult T-cell leukemia/lymphoma (ATL)Adult T-cell Leukemia/Lymphoma (ATL)JPRN-UMIN000004061PS341-ATL Coordinating Office25
已完成
不适用
A phase II study of PAD therapy (bortezomib, doxorubicin, and dexamethasone) for relapsed or refractory multiple myeloma.JPRN-UMIN000004514Department of Hematology and Respiratory Medicine, Kochi University20
已完成
2 期
Bortezomib Plus Rituximab for EBV+ PTLDPost-transplant Lymphoproliferative DiseaseSolid Organ TransplantStem Cell Transplant (Bone Marrow Transplant)Epstein Barr Virus InfectionsNCT01058239Massachusetts General Hospital7
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDRewly diagnosed Waldenstrom's macroglobulinemia (WM)MedDRA version: 8.1Level: LLTClassification code 10054695Term: Waldenstrom's macroglobulinemiaEUCTR2006-003563-31-NLEuropean Myeloma Network90
进行中（未招募）
不适用
Phase II Study of Combination Bortezomib (VELCADE, PS-341), Dexamethasone, and Rituximab (MabThera) (BDR) in Patients with previously untreated Waldenstrom’s Macroglobulinemia (WM). - protocol BDREUCTR2006-003563-31-DKEuropean Myeloma Network90